A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

The Boston Arts Academy Foundation closed its Building Our Future fundraising campaign, surpassing its $35 million goal, ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Rhythm Pharmaceuticals, Inc. may be ripe in a year. At that time, setmelanotide should be approved for HO in the U.S. and ...

Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

BOSTON, June 9, 2025 – The Renaissance Boston Seaport District recently debuted its stunning new rooms… Scouting America is proud to announce that Bob Rivers, Executive Chair and Chair of the ...

GSK GSK-1.00 % decrease; red down pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs.

Boston Pharmaceuticals licensed the medicine from Novartis in 2020, with GSK now on the hook for success-based milestone payments and tiered royalties to the Swiss drugmaker.

3 Key Takeaways . GSK has acquired efimosfermin alfa, a Phase III-ready FGF21 analog from Boston Pharmaceuticals, in a deal valued at up to $2 billion, expanding its hepatology pipeline to target ...

Boston Pharmaceuticals’ lead investigational agent, efimosfermin alfa, is a once-monthly subcutaneous injection of a long-acting variant of human fibroblast growth factor 21 (FGF21) that regulates ...